Calliditas Therapeutics AB ADR (CALT): Price and Financial Metrics

Calliditas Therapeutics AB ADR (CALT): $18.21

1.00 (+5.80%)

POWR Rating

Component Grades













CALT Stock Price Chart Interactive Chart >

Price chart for CALT

CALT Price/Volume Stats

Current price $18.21 52-week high $27.50
Prev. close $17.21 52-week low $10.82
Day low $18.00 Volume 6,900
Day high $18.45 Avg. volume 12,419
50-day MA $15.43 Dividend yield N/A
200-day MA $17.01 Market Cap 538.63M

Calliditas Therapeutics AB ADR (CALT) Company Bio

Calliditas Therapeutics AB provides pharmaceutical products for patients with niche indications. It focuses on development and commercialization of the product candidate Nefecon intended for treatment of patients with the inflammatory renal disease IgA nephropathy. The company was founded by Mikael Bender and Bengt Åke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.

CALT Latest News Stream

Event/Time News Detail
Loading, please wait...

CALT Latest Social Stream

Loading social stream, please wait...

View Full CALT Social Stream

Latest CALT News From Around the Web

Below are the latest news stories about CALLIDITAS THERAPEUTICS AB that investors may wish to consider to help them evaluate CALT as an investment opportunity.

Calliditas' partner Everest Medicine's New Drug Application for Nefecon is accepted by the China NMPA

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Chinese regulatory authority National Medical Products Administration ("NMPA") has accepted Everest Medicines' (HKEX 1952.HK, "Everest") New Drug Application ("NDA") for Nefecon. The acceptance brings Nefecon, approved and marketed in the U.S. under the name TARPEYO® and in the E.U. as Kinpeygo®, an important step closer to potentially becoming the first-ever approved therapeutic option in

Yahoo | November 15, 2022

Calliditas Therapeutics: Interim Report Q3, 2022

"On July 15th the European Commission issued the conditional marketing authorization for Kinpeygo, which marked the first time that any drug has achieved approval for this rare disease in EU. We immediately started the process of transferring the market authorization to our European partner, STADA Arzneimittel AG, in order to enable a launch in Europe as quickly as possible. STADA is initially launching the product in Germany, with other European countries to follow over time.

Yahoo | November 14, 2022

Key Opinion Leader Fireside Chat with Professor Richard Lafayette on the US IgAN Treatment Landscape

Calliditas Therapeutics AB (publ) ("Calliditas") today announced that it will host a Key Opinion Leader (KOL) Fireside Chat on the IgA Nephropathy (IgAN) treatment landscape in the US on Tuesday, November 8th, 2022 at 1:30pm Eastern Time.

Yahoo | November 7, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

William White on InvestorPlace | October 21, 2022

Why Snap Shares Are Trading Sharply Lower; Here Are 25 Stocks Moving Premarket

Gainers Statera Biopharma, Inc. (NASDAQ: STAB ) rose 40.9% to $0.2160 in pre-market trading. Statera Biopharma recently signed a binding Memorandum of Understanding with Holobeam Technologies Inc. Energy Focus, Inc (NASDAQ: EFOI ) shares rose 31.6% to $0.5312 in pre-market trading. Energy Focus, last month, named Lesley Matt as CEO. FedNat Holding Company (NASDAQ: FNHC ) rose 18.1% to $0.66 in pre-market trading after dipping over 8% on Thursday. Veris Residential, Inc. (NYSE: VRE ) shares rose 18% to $14.65 in pre-market trading. Kushner Cos. offered to acquire Veris Residential for $16 per share, the Wall Street Journal reported. American Rebel Holdings, Inc. (NASDAQ: AREB ) rose 16.6% to $0.3389 in pre-market trading. American Rebel shares gained around 5% on Thursday after the compa...

Benzinga | October 21, 2022

Read More 'CALT' Stories Here

CALT Price Returns

1-mo 28.06%
3-mo 9.37%
6-mo -2.41%
1-year 5.26%
3-year N/A
5-year N/A
YTD -26.45%
2021 -26.35%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6733 seconds.